Novel Autoantibodies in Systemic Autoimmune Diseases: Challenges and Perspectives
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: 31 December 2025 | Viewed by 980
Special Issue Editors
Interests: Sjogren's disease; inflammatory myopathies; autoantibodies; type I IFN; systemic autoimmune disorders
Special Issues, Collections and Topics in MDPI journals
Interests: Sjogren's disease; inflammatory myopathies; autoantibodies; type I IFN; systemic autoimmune disorders
Immunogenetics Laboratory, 1st Department of Neurology, Medical School of National and Kapodistrian University of Athens, Aeginition Hospital, Athens, Greece
Interests: systemic autoimmune diseases; autoimmune diseases of CNS; type I interferons and immunopharmacology
Special Issue Information
Dear Colleagues,
Autoantibodies play a crucial role in the pathogenesis and classification of autoimmune diseases, yet new autoantibody profiles have introduced complexities in diagnosis and management. Clinicians encounter difficulties differentiating between overlapping syndromes and recognizing the diagnostic significance of lower titer autoantibodies when forming a conclusive diagnosis.
Substantial evidence so far suggests that both innate and adaptive immunity play significant roles in the pathogenesis of systemic autoimmune diseases like systemic lupus erythematosus, Sjögren’s disease, systemic sclerosis, and inflammatory myopathies with activation of type I interferon and B cell pathways being key pathogenetic determinants. Novel autoantibodies targeting nuclear, nucleolar, and cytoplasmic components are continually being identified. Although ongoing research is focused on understanding how these autoantibodies contribute to clinical presentation and prognosis, their influence on other facets of autoimmune disease pathogenesis—such as early diagnosis and treatment strategies—remains largely unclear.
This issue compiles a series of original research articles, reviews, and case studies that delve into the implications of novel autoantibodies in systemic autoimmunity and, more specifically, the diagnostic utility of these autoantibodies, their association with novel disease phenotypes and their potential as biomarkers for disease progression and treatment response. As autoimmunity continues to evolve, understanding the role of novel autoantibodies will be vital in refining diagnostic criteria and improving patient management.
This Special Issue aims to foster dialogue and collaboration among researchers and clinicians, ultimately enhancing our understanding of systemic autoimmune disorders in the context of novel autoantibody research. We hope it is a valuable resource for advancing the field and improving patient outcomes.
Dr. Clio Mavragani
Dr. Nikolaos Marketos
Dr. Charalampos Skarlis
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- autoantibodies
- autoimmune diseases
- innate and adaptive immunity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
